Please select the option that best describes you:
What front line therapy would you recommend for a patient with CLL on chronic dual antiplatelet therapy?
How would your choice of therapy differ (if at all) for high vs low risk disease?
Would the specific anti-platelet agents used influence your choice above?
Are there any circumstances where you would give a BTK inhibitor with concurrent dual anti-platelet therapy?
Answer from: Medical Oncologist at Academic Institution
Given the bleeding risks associated with BTKi, I personally may prefer venetoclax-based therapy if feasible, in treating patients who require dual antiplatelet therapy (DAPT). This is based on safety considerations.
I consider both BTKi-based therapy and venetoclax-based therapy great options for f...
Sign in or Register to read more